Magainin
| Magainin | |
|---|---|
| Identifiers | |
| Symbol | Magainin |
TCDB | 1.C.16 |
| OPM superfamily | 211 |
| OPM protein | 2mag |
The magainins are a class of antimicrobial peptides found in the African clawed frog (Xenopus laevis).[1] The peptides are cationic, generally lack a stable conformation in water but form amphipathic α-helix in membranes; their mechanism against micro-organisms is unclear but they disrupt the cell membranes of a broad spectrum of bacteria, protozoa, and fungi.[2]
They were independently discovered at around the same time by the labs of
Zasloff helped found a company, Magainin Pharmaceuticals (subsequently called Genaera) to develop magainins into drugs.[4] One candidate was an analog of magainin called pexiganan (MSI-78) that the company developed as a topical agent for infected diabetic foot ulcers; in 1999 the FDA rejected the application because pexiganan was not better than standard treatments.[2][5][6] Another company, Dipexium Pharmaceuticals, ran further phase III clinical trials for the same use, which failed in 2016.[7]
References
- ^ Magainins at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
- ^ PMID 22036891.
- ^ Interviewed in 1987, Zasloff explained: "I used it because it came from the skin and it was shielding, in my opinion. What the hell, I hadn't heard a Hebrew name in science before" (Susan Okie (July 30, 1987). "Frog's Skin Yields Powerful Antibiotic". The Washington Post.). In a later interview, his wife, Barbara Zasloff, added: "Tradition would have it that he would have given it a Latin or Greek name. We both felt that he comes from a Hebrew tradition and it would be very appropriate to give it a Hebrew name" (Susan Okie (February 16, 1988). "A Man and His Frogs". The Washington Post.).
- ^ George J (April 29, 2009). "Biotech Genaera shutting down: Never brought drug to market". Philadelphia Business Journal.
- PMID 12612596.
- ^ "Pexiganan". AdisInsight. Retrieved 16 January 2018.
- ^ "Dipexium's Diabetic Foot Ulcer Candidate Fails Phase III Trials". GEN. October 25, 2016.